These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34874825)

  • 1. Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination.
    Galloway J; Raine T; Rivett L; Roberts J; Dews SA; Choy EH
    Clin Exp Rheumatol; 2022 Jul; 40(7):1432-1441. PubMed ID: 34874825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention.
    Colombel JF
    Inflamm Bowel Dis; 2018 Sep; 24(10):2173-2182. PubMed ID: 29788127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies.
    Gialouri CG; Moustafa S; Thomas K; Hadziyannis E; Vassilopoulos D
    Rheumatol Int; 2023 Mar; 43(3):421-435. PubMed ID: 36635577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
    Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
    Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study.
    Chen PK; Chang SH; Chen YM; Chen HH; Huang PH; Huang CC; Yeo KJ; Lan JL; Chen DY
    Clin Rheumatol; 2024 Aug; 43(8):2503-2511. PubMed ID: 38954278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
    Calabrese LH; Abud-Mendoza C; Lindsey SM; Lee SH; Tatulych S; Takiya L; Iikuni N; Soma K; Luo Z; Fleischmann R
    Arthritis Care Res (Hoboken); 2020 Mar; 72(3):353-359. PubMed ID: 31207152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
    Winthrop KL; Melmed GY; Vermeire S; Long MD; Chan G; Pedersen RD; Lawendy N; Thorpe AJ; Nduaka CI; Su C
    Inflamm Bowel Dis; 2018 Sep; 24(10):2258-2265. PubMed ID: 29850873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids.
    Curtis JR; Xie F; Yang S; Bernatsky S; Chen L; Yun H; Winthrop K
    Arthritis Care Res (Hoboken); 2019 Sep; 71(9):1249-1254. PubMed ID: 30295428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
    Bing N; Zhou H; Chen X; Hirose T; Kochi Y; Tsuchida Y; Ishigaki K; Sumitomo S; Fujio K; Zhang B; Valdez H; Vincent MS; Martin D; Clark JD
    Arthritis Rheumatol; 2021 Jul; 73(7):1155-1166. PubMed ID: 33455090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials.
    Winthrop KL; Nash P; Yamaoka K; Mysler E; Khan N; Camp HS; Song Y; Suboticki JL; Curtis JR
    Ann Rheum Dis; 2022 Feb; 81(2):206-213. PubMed ID: 34615638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
    Bechman K; Subesinghe S; Norton S; Atzeni F; Galli M; Cope AP; Winthrop KL; Galloway JB
    Rheumatology (Oxford); 2019 Oct; 58(10):1755-1766. PubMed ID: 30982883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors.
    Källmark H; Bergström T; Nagel J; Gullstrand B; Einarsson JT; Bengtsson AA; Kapetanovic MC
    Rheumatology (Oxford); 2024 Jul; 63(7):2024-2033. PubMed ID: 37851412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology and safety of tofacitinib in ulcerative colitis.
    López-Sanromán A; Esplugues JV; Domènech E
    Gastroenterol Hepatol; 2021 Jan; 44(1):39-48. PubMed ID: 32829958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea.
    Kim YE; Kim YJ; Jeong DH; Kim S; Kim MJ; Kim HH; Jo KW; Park SH; Hong S
    Semin Arthritis Rheum; 2024 Apr; 65():152362. PubMed ID: 38281468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation.
    Baumrin E; Van Voorhees A; Garg A; Feldman SR; Merola JF
    J Am Acad Dermatol; 2019 Jul; 81(1):102-110. PubMed ID: 30885757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review.
    Winthrop KL; Tanaka Y; Lee EB; Wollenhaupt J; Al Enizi A; Azevedo VF; Curtis JR
    Clin Exp Rheumatol; 2022 Jan; 40(1):162-172. PubMed ID: 34128786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment.
    Winthrop KL; Curtis JR; Yamaoka K; Lee EB; Hirose T; Rivas JL; Kwok K; Burmester GR
    Rheumatol Ther; 2022 Feb; 9(1):243-263. PubMed ID: 34870800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study.
    Uchida T; Iwamoto N; Fukui S; Morimoto S; Aramaki T; Shomura F; Aratake K; Eguchi K; Ueki Y; Kawakami A
    Rheumatology (Oxford); 2023 Oct; 62(10):3358-3365. PubMed ID: 36794922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
    Winthrop KL; Vermeire S; Long MD; Panés J; Ng SC; Kulisek N; Mundayat R; Lawendy N; Vranic I; Modesto I; Su C; Melmed GY
    Inflamm Bowel Dis; 2023 Jan; 29(1):85-96. PubMed ID: 35648151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
    Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
    Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.